Raymond James Trust N.A. grew its position in Pfizer (NYSE:PFE) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 514,368 shares of the biopharmaceutical company’s stock after acquiring an additional 6,056 shares during the quarter. Pfizer comprises 1.3% of Raymond James Trust N.A.’s holdings, making the stock its 12th largest position. Raymond James Trust N.A.’s holdings in Pfizer were worth $18,631,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Beach Investment Management LLC. purchased a new position in Pfizer during the second quarter worth approximately $5,214,000. Hanson McClain Inc. lifted its position in Pfizer by 2.0% during the second quarter. Hanson McClain Inc. now owns 13,898 shares of the biopharmaceutical company’s stock worth $467,000 after buying an additional 276 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its position in Pfizer by 3.4% during the second quarter. Alpha Omega Wealth Management LLC now owns 108,815 shares of the biopharmaceutical company’s stock worth $3,655,000 after buying an additional 3,534 shares in the last quarter. Usca Ria LLC lifted its position in Pfizer by 0.3% during the second quarter. Usca Ria LLC now owns 332,964 shares of the biopharmaceutical company’s stock worth $11,184,000 after buying an additional 1,033 shares in the last quarter. Finally, Intrust Bank NA raised its position in Pfizer by 2.5% in the second quarter. Intrust Bank NA now owns 65,268 shares of the biopharmaceutical company’s stock valued at $2,192,000 after purchasing an additional 1,596 shares during the period. Institutional investors and hedge funds own 71.19% of the company’s stock.
In other news, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total value of $1,515,973.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,037 shares of company stock valued at $9,064,785. Insiders own 0.06% of the company’s stock.
NYSE:PFE opened at $36.33 on Wednesday. The stock has a market cap of $216,208.05, a PE ratio of 13.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.90. Pfizer has a 1 year low of $31.67 and a 1 year high of $39.43. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 EPS. research analysts forecast that Pfizer will post 2.96 earnings per share for the current year.
A number of brokerages have recently weighed in on PFE. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. SunTrust Banks reissued a “hold” rating and set a $40.00 target price (up from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Morgan Stanley boosted their target price on Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. UBS set a $42.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Societe Generale set a $40.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $39.20.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/04/18/raymond-james-trust-n-a-grows-stake-in-pfizer-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.